Levothyroxine exposure was associated with a decreased risk of AD in all neuroinflammation-related cohorts and the all individuals with neuroinflammation-related conditions (Figure 3A; hazard ratios [HRs] ≤0.90 and P-values <0.01). Mirabegron exposure was associated with a decreased risk of AD in HS cohort, TBI cohort, and all patients with neuroinflammation-related conditions (Figure 3B; HRs ≤0.69 and P-values ≤0.01). Ropinirole exposure was associated with a decreased risk of AD in epilepsy cohort and all patients with neuroinflammation-related conditions (Figure 3C; HRs ≤0.81 and P-values ≤0.02). All of levothyroxine exposure, mirabegron exposure, and ropinirole exposure were not associated with AD in individuals without neuroinflammation-related conditions (Figure 3A–C).
